Advertisement
Canada markets close in 2 hours 7 minutes

  • S&P/TSX

    21,845.57
    +137.13 (+0.63%)
     

  • S&P 500

    4,996.10
    -15.02 (-0.30%)
     

  • DOW

    38,075.72
    +300.34 (+0.80%)
     

  • CAD/USD

    0.7279
    +0.0016 (+0.22%)
     

  • CRUDE OIL

    83.55
    +0.82 (+0.99%)
     

  • Bitcoin CAD

    88,723.95
    +2,021.48 (+2.33%)
     

  • CMC Crypto 200

    1,379.58
    +66.96 (+5.10%)
     

  • GOLD FUTURES

    2,409.90
    +11.90 (+0.50%)
     

  • RUSSELL 2000

    1,944.28
    +1.32 (+0.07%)
     

  • 10-Yr Bond

    4.6290
    -0.0180 (-0.39%)
     

  • NASDAQ

    15,414.52
    -186.98 (-1.20%)
     

  • VOLATILITY

    18.63
    +0.63 (+3.50%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6827
    +0.0006 (+0.09%)
     
MARKETS LIVE BLOG:

S&P 500 SLIPS BELOW 5,000; NASDAQ SINKS ON NETFLIX DRAG

Fed's Goolsbee says 'It makes sense to wait' before cutting rates

United States Regenerative Medicine Markets Report 2021

Research and Markets
·2 min read

Dublin, Sept. 28, 2021 (GLOBE NEWSWIRE) -- The "United States Regenerative Medicine Market, Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.

United States regenerative medicine market is expected to witness robust growth until 2026

The United States regenerative medicine market is driven by the growing popularity of stem cell-based therapies. Additionally, the use of regenerative medicines for treating chronic diseases, acute insults and maladies is further propelling the market in the country.

The United States regenerative medicine market is segmented based on type, material, application, company and region. Based on type, the market can be categorized into cell-based immunotherapy & cell therapy products, gene therapy products, tissue-engineered products and others.

ADVERTISEMENT

The cell-based immunotherapy & cell therapy products segment is expected to dominate the market during forecast years on account of the growing demand for cell-based immunotherapies and establishment of cures act by FDA to streamline the regenerative medicine market. The segment has the most promising future on account of its capability to restore the lost function of tissues and organs.

Based on application, the market can be fragmented into musculoskeletal disorders, wound care, oncology, ocular disorders, diabetes, dermatology and others. The dermatology application segment is expected to hold a significant market share during the forecast years. This can be attributed to the presence of easy grafting techniques for dermatological wounds and diseases.

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in United States regenerative medicine market.

Major players operating in the United States regenerative medicine market include

  • Integra LifeSciences Holdings Corporation

  • Stryker Corporation

  • Amgen, Inc

  • AbbVie, Inc

  • Roche Diagnostics Corporation

  • Gilead Sciences, Inc

  • Astellas Pharma, Inc

  • bluebird bio, Inc

  • Medtronic USA, Inc

  • Organogenesis Holdings Inc

  • MiMedx Group Inc

  • Vericel Corporation

Report Scope:

Years considered for this report:

  • Historical Years: 2016-2019

  • Base Year: 2020

  • Estimated Year: 2021

  • Forecast Period: 2022-2026

United States Regenerative Medicine Market, By Type:

  • Cell Therapies

  • Gene Therapies

  • Progenitor & Stem Cell Therapies

  • Tissue Engineered Products

United States Regenerative Medicine Market, By Material:

  • Biologically Derived Material

  • Synthetic Material

  • Pharmaceuticals

  • Genetically Engineered Material

United States Regenerative Medicine Market, By Application:

  • Musculoskeletal Disorder

  • Wound Care

  • Oncology

  • Ophthalmology

  • Neurology

  • Dermatology

  • Others

United States Regenerative Medicine Market, By Region:

  • North-East

  • Mid-West

  • West

  • South

For more information about this report visit https://www.researchandmarkets.com/r/a3695r


CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900